“With this launch, Alverno sets a new standard in the quality of cancer care, further demonstrating its leadership and commitment to its patients by implementing an advanced clinical-grade artificial intelligence solution to ensure the best possible results. Artificial intelligence and digital pathology technologies have become an essential part of cancer care programs, and their adoption is a vision shared by both Alverno and Ibex ”.
Ibex solutions help address two major challenges in the field: human error and a shortage of pathologists.
“When a person shows potential symptoms of cancer, the next step is a biopsy, an analysis of a sample of the affected tissues,” Ibex CEO Joseph Mossel told The Jerusalem Post in March 2020, when the Galen Prostate solution received the CE-IVD Mark in the European Union.
“Examination of the sample must be done by a pathologist using a microscope. Pathology is a complex medical discipline that requires years of training, and the world is facing a shortage of these specialists, even in countries like the United States and the United Kingdom. There is a growing gap between supply and demand ”.
In June 2020, Ibex partnered with Medipath, the largest private pathology laboratory network in France, to implement Galen for cancer screening.
Galen received approval in May 2021 in Europe for the diagnosis of breast cancer after Maccabi Healthcare Services in Israel and the Institut Curie in France conducted a clinical study.
“We are impressed with the successful results of the study and the performance of Galen Breast,” said Anne Vincent-Salomon, director of pathology at the Institut Curie and principal investigator on the study, in a news release. “Our team demonstrated that Ibex AI technology goes beyond cancer detection and provides accurate information on tumor type, nuclear staging of carcinomas in situ and more.
“I am confident that artificial intelligence will support breast pathologists and provide benefit to cancer patients in multiple segments of the diagnostic workflow and I look forward to seeing this technology widely adopted in the field.”
Reproduction authorized with the following mention: © EnlaceJudío
Related
–
